Priya Ganesh Kumar*

Department of Preventive Oncology, Medical Director of Sainiwas Healthcare, India

*Corresponding Author: Priya Ganesh Kumar, Department of Preventive Oncology, Medical Director of Sainiwas Healthcare, India.

Received: April 22, 2022; Published: May 06, 2022

Abstract

WHO Mission statement of Cervical cancer Elimination by 2030 has been a historic moment and has created an impactful global awareness regarding this deadly disease. The triple formula of 90-70-90 has been designed to have a 30% reduction in mortality from cervical cancer to be achieved by 2030. The goal of Cervical cancer elimination is to bring down the cases of cervical cancer below 4 per 100,000 woman. To achieve this goal the targets laid down is 90% coverage of girls fully vaccinated with HPV Vaccine by 15 years of age, 70% of women screened with an HPV test at 35 and 45 years of age and all managed properly, 90% of women identified with preinvasive disease receive adequate treatment and follow up. It is now an established fact that cervical cancer is caused by persistent infection with high-risk HPV strains. 4 out of 5 women in our country is affected with HPV, HPV being a sexually transmitted virus. Persistent high risk (HR) HPV is necessary for development of precursor lesions and cervical cancer. The major steps in cervical carcinogenesis include HPV infection, HPV persistence for a certain period of time, progression to precancer and invasion

Keywords:HPV; Cervical Cancer; Screening

References

1. Lancet Oncology12 (2018): 89-306.
2. Peter A. “Medscape Global Prevalence of high risk HPV in women with normal cytology” (2020).
3. Bruni L and Diaz M. “Meta-analysis of 1 million women with normal cytological findings”. The Journal of Infectious Diseases 12 (2015): 1789-1799.
4. PE Gravit. “The known unknown of HPV natural history”. Journal of Clinical Investigation12 (2011): 4593-4599.
5. Neerja Bhatla., et al. “Screening and management of preinvasive lesions of the cervix: Good clinical practice recommendations from FOGSI HTTPS”. 46.2 (2020): 201-214.
6. Sankarnarayanan R., et al. “HPV screening for cervical cancer in rural India”. The New England Journal of Medicine 360 (2009): 1385-1394.
7. Wright TC and Stoler MH. “The Athena human papillomavirus study”. American Journal of Obstetrics and Gynecology 206 (2012): 46-e1.

Citation

Citation: Priya Ganesh Kumar. “HPV Test As Primary Screening Tool". Acta Scientific Women's Health 4.6 (2022): 31-34.

Copyright

Copyright: © 2022 Priya Ganesh Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.